Angiogenesis Inhibitors: Current Strategies and Future Prospects

被引:399
作者
Cook, Kristina M. [1 ,2 ]
Figg, William D. [1 ]
机构
[1] NCI, Mol Pharmacol Sect, Med Oncol Branch & Affiliates, NIH, Bethesda, MD 20892 USA
[2] Univ New S Wales, Adult Canc Program, Lowy Canc Res Ctr, Sydney, NSW, Australia
关键词
ENDOTHELIAL-GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TYROSINE KINASE INHIBITORS; CELL LUNG-CANCER; PHASE-III TRIAL; FARNESYL-PROTEIN TRANSFERASE; VASCULAR-PERMEABILITY FACTOR; TUMOR-GROWTH; FACTOR; 1-ALPHA; FACTOR EXPRESSION;
D O I
10.3322/caac.20075
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis has become an attractive target for drug therapy because of its key role in tumor growth. An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (eg, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and epidermal growth factor), receptor tyrosine kinases, and transcription factors such as hypoxia inducible factor, as well as molecules involved in mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling. Pharmacologic agents have been identified that target these pathways, yet for some agents (notably thalidomide), an understanding of the specific mechanisms of antitumor action has proved elusive. The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy. CA Cancer J Clin 2010;60:222-243. (C) 2010 American Cancer Society, Inc.
引用
收藏
页码:222 / 243
页数:22
相关论文
共 210 条
[1]   NUCLEOTIDE-SEQUENCE OF A BOVINE CLONE ENCODING THE ANGIOGENIC PROTEIN, BASIC FIBROBLAST GROWTH-FACTOR [J].
ABRAHAM, JA ;
MERGIA, A ;
WHANG, JL ;
TUMOLO, A ;
FRIEDMAN, J ;
HJERRILD, KA ;
GOSPODAROWICZ, D ;
FIDDES, JC .
SCIENCE, 1986, 233 (4763) :545-548
[2]  
Aebersold DM, 2001, CANCER RES, V61, P2911
[3]   Role of platelet-derived growth factors in physiology and medicine [J].
Andrae, Johanna ;
Gallini, Radiosa ;
Betsholtz, Christer .
GENES & DEVELOPMENT, 2008, 22 (10) :1276-1312
[4]  
[Anonymous], J CLIN ONCOL S
[5]   Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system [J].
Augustin, Hellmut G. ;
Koh, Gou Young ;
Thurston, Gavin ;
Alitalo, Kari .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009, 10 (03) :165-177
[6]   Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].
Bartlett, JB ;
Dredge, K ;
Dalgleish, AG .
NATURE REVIEWS CANCER, 2004, 4 (04) :314-322
[7]   Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].
Bauer, KS ;
Dixon, SC ;
Figg, WD .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) :1827-1834
[8]   An orally delivered small-molecule formulation with antiangiogenic and anticancer activity [J].
Benny, Ofra ;
Fainaru, Ofer ;
Adini, Avner ;
Cassiola, Flavia ;
Bazinet, Lauren ;
Adini, Irit ;
Pravda, Elke ;
Nahmias, Yaakov ;
Koirala, Samir ;
Corfas, Gabriel ;
D'Amato, Robert J. ;
Folkman, Judah .
NATURE BIOTECHNOLOGY, 2008, 26 (07) :799-807
[9]  
Berger W, 1999, INT J CANCER, V83, P415, DOI 10.1002/(SICI)1097-0215(19991029)83:3<415::AID-IJC19>3.0.CO
[10]  
2-Y